Papers
Topics
Authors
Recent
Search
2000 character limit reached

Utilizing AI and Social Media Analytics to Discover Adverse Side Effects of GLP-1 Receptor Agonists

Published 1 Apr 2024 in q-bio.QM, cs.AI, cs.CL, cs.IR, cs.LG, and cs.SI | (2404.01358v1)

Abstract: Adverse side effects (ASEs) of drugs, revealed after FDA approval, pose a threat to patient safety. To promptly detect overlooked ASEs, we developed a digital health methodology capable of analyzing massive public data from social media, published clinical research, manufacturers' reports, and ChatGPT. We uncovered ASEs associated with the glucagon-like peptide 1 receptor agonists (GLP-1 RA), a market expected to grow exponentially to $133.5 billion USD by 2030. Using a Named Entity Recognition (NER) model, our method successfully detected 21 potential ASEs overlooked upon FDA approval, including irritability and numbness. Our data-analytic approach revolutionizes the detection of unreported ASEs associated with newly deployed drugs, leveraging cutting-edge AI-driven social media analytics. It can increase the safety of new drugs in the marketplace by unlocking the power of social media to support regulators and manufacturers in the rapid discovery of hidden ASE risks.

Definition Search Book Streamline Icon: https://streamlinehq.com
References (85)
  1. World Health Organization. Obesity and overweight. 2021. Accessed October 5, 2023.
  2. Centers for Disease Control and Prevention. Type 2 diabetes. 2023. Accessed October 5, 2023.
  3. Variations in comorbidity burden in people with type 2 diabetes over disease duration: A population-based analysis of real world evidence. EClinicalMedicine, 52, 2022.
  4. Pradeep Khand and Bo Feng. The association of obesity with type 2 diabetes: A review. International Journal of Science Inventions Today, 9:61–74, 2020.
  5. Economic impacts of overweight and obesity: Current and future estimates for 161 countries. BMJ Global Health, 7(9):e009773, 2022.
  6. GLP-1 agonists for weight loss: Pharmacology and clinical implications. Advances in Therapy, 40(3):723–742, 2023.
  7. GLP-1 receptor agonists: An updated review of head-to-head clinical studies. Therapeutic Advances in Endocrinology and Metabolism, 12:2042018821997320, 2021.
  8. J. Pritchett. 2022 prescription trends. May 2023. Accessed October 5, 2023.
  9. First-time prescribing of GLP-1 receptor agonists from 2018-2023: A descriptive analysis. medRxiv, pages 2023–08, 2023.
  10. Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: A Google Trends analysis. Aesthetic Surgery Journal, pages 211–215, 2023.
  11. Ant Cabral Lopes. Gastrointestinal disorders potentially associated with semaglutide: An analysis from the Eudravigilance Database. Expert Opinion on Drug Safety, pages 1–7, 2023.
  12. GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: A system review and network meta-analysis. Frontiers in Endocrinology, 14, 2023.
  13. Novo Nordisk. Ozempic® (semaglutide) approved in the US. 2017. Accessed October 5, 2023.
  14. Adverse event detection in drug development: Recommendations and obligations beyond phase 3. American Journal of Public Health, 98(8):1366–1371, 2008.
  15. James E Ridings. The thalidomide disaster, lessons from the past. Teratogenicity Testing: Methods and Protocols, pages 575–586, 2013.
  16. Safety issues related to intravenous contrast agent use in magnetic resonance imaging. Pediatric Radiology, 51:736–747, 2021.
  17. Selective COX-2 inhibitors: Road from success to controversy and the quest for repurposing. Pharmaceuticals, 15(7):827, 2022.
  18. Eduardo Ortiz. Market withdrawal of Vioxx: Is it time to rethink the use of COX-2 inhibitors? Journal of Managed Care Pharmacy, 10(6):551–554, 2004.
  19. FDA Adverse Event Reporting System (FAERS) Public Dashboard. 2023. Accessed October 5, 2023.
  20. The SIDER database of drugs and side effects. Nucleic Acids Research, 44(D1):D1075–D1079, 2016.
  21. Mining MEDLINE: Abstracts, sentences, or phrases? In Biocomputing 2002, pages 326–337. World Scientific, 2001.
  22. Elsevier. Embase Database. 2023. Accessed October 6, 2023.
  23. Incomplete evidence: The inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Medical Research Methodology, 1:1–6, 2001.
  24. Computational drug repositioning based on side-effects mined from social media. PeerJ Computer Science, 2:e46, 2016.
  25. Perihan Elif Ekmekci. An increasing problem in publication ethics: Publication bias and editors’ role in avoiding it. Medicine, Health Care and Philosophy, 20:171–178, 2017.
  26. Dealing with the positive publication bias: Why you should really publish your negative results. Biochemia Medica, 27(3):447–452, 2017.
  27. Recognizing, investigating and dealing with incomplete and biased reporting of clinical research: From Francis Bacon to the WHO. Journal of the Royal Society of Medicine, 104(12):532–538, 2011.
  28. The use of questionnaires for measuring patient-reported side effects of drugs: Its importance and methodological challenges. Pharmacoepidemiology and Drug Safety, 17(3):278–296, 2008.
  29. Exploring the relationship between drug side-effects and therapeutic indications. In AMIA annual symposium proceedings, volume 2013, page 1568. American Medical Informatics Association, 2013.
  30. The use of social media in detecting drug safety–related new black box warnings, labeling changes, or withdrawals: Scoping review. JMIR Public Health and Surveillance, 7(6):e30137, 2021.
  31. Analysis of online user discussions on Reddit associated with the transition of use between HIV PrEP therapy. Frontiers in Public Health, 11, 2023.
  32. Reddit on prep: Posts about pre-exposure prophylaxis for HIV from Reddit users, 2014–2019. AIDS and Behavior, pages 1–11, 2021.
  33. Experiences and perspectives of individuals accessing CAR-T cell therapy: A qualitative analysis of online Reddit discussions. Journal of Cancer Policy, 30:100303, 2021.
  34. Utilizing Twitter data for analysis of chemotherapy. International Journal of Medical Informatics, 120:92–100, 2018.
  35. Thematic analysis of Reddit content about buprenorphine-naloxone using manual annotation and natural language processing techniques. Journal of Addiction Medicine, 2022.
  36. Mining frequency of drug side effects over a large Twitter dataset using Apache Spark. In IEEE/ACM, editor, Proceedings of the 2017 IEEE/ACM International Conference on Advances in Social Networks Analysis and Mining, pages 915–924, 2017.
  37. Mining twitter data for potential drug effects. In Advanced Data Mining and Applications: 9th International Conference, ADMA 2013, Hangzhou, China, December 14-16, 2013, Proceedings, Part I 9, pages 434–443. Springer, 2013.
  38. Katie Elson Anderson. Ask me anything: What is reddit? Library Hi Tech News, 32(5):8–11, 2015.
  39. Self-disclosure and social media: Motivations, mechanisms and psychological well-being. Current Opinion in Psychology, 31:110–115, 2020.
  40. Ann E Schlosser. Self-disclosure versus self-presentation on social media. Current Opinion in Psychology, 31:1–6, 2020.
  41. John Suler. The online disinhibition effect. Cyberpsychology and Behavior, 7(3):321–326, 2004.
  42. Adverse events of GLP-1 receptor agonists for weight loss: Twitter and a national pharmacovigilance database. Drug Targets and Therapeutics, 2(1):41–48, 2023.
  43. Mining potentially unreported effects from Twitter posts through relational similarity: A case for opioids. In 2020 IEEE International Conference on Bioinformatics and Biomedicine (BIBM), pages 2603–2609. IEEE, 2020.
  44. Towards large-scale twitter mining for drug-related adverse events. In Proceedings of the 2012 international workshop on Smart health and wellbeing, pages 25–32, 2012.
  45. Social media as pharmacovigilance: The potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders. Journal of Studies on Alcohol and Drugs, pages 19–23, 2023.
  46. Areas of interest and attitudes toward antiobesity drugs: Thematic and quantitative analysis using Twitter. Journal of Medical Internet Research, 23(10):e24336, 2021.
  47. Signal fusion for social media analysis of adverse drug events. IEEE Intelligent Systems, 29(2):74–80, 2014.
  48. Does social media accelerate product recalls? Evidence from the pharmaceutical industry. Information Systems Research, 33(3):954–977, 2022.
  49. Further research on internet searches for on-and off-label use of weight-loss medications. Aesthetic Surgery Journal, 43(11):NP977–NP978, 2023.
  50. Semaglutide and social media: Implications for young women with polycystic ovarian syndrome. The Lancet Child and Adolescent Health, 7(5):301–303, 2023.
  51. Descriptive analysis of TikTok videos posted under the hashtag# Ozempic. Journal of Medicine, Surgery, and Public Health, 1:100013, 2023.
  52. Jayna Lennon. Can you stomach it? A content analysis of TikTok videos and comments about weight loss with Ozempic. 2023.
  53. GLP-1 receptor agonists and related mental health issues and insights from a range of social media platforms using a mixed-methods approach. Brain Sciences, 13(11):1503, 2023.
  54. Healthcare NER models using language model pretraining. arXiv preprint arXiv:1910.11241, 2019.
  55. A survey on deep learning for named entity recognition. IEEE Transactions on Knowledge and Data Engineering, 34(1):50–70, 2020.
  56. James Temperton. GPT-3: How does the new language model work? BBC Science Focus, 2023. Accessed: February 5, 2024.
  57. Large language models in medicine: The potentials and pitfalls: A narrative review. Annals of Internal Medicine, 2024.
  58. Benefits, limits, and risks of GPT-4 as an AI chatbot for medicine. New England Journal of Medicine, 388(13):1233–1239, 2023.
  59. Andrew Joseph. How ChatGPT 4 is transforming health care and medical education. Stat News, 2023. Accessed: February 5, 2024.
  60. Mike Miliard. Epic, Microsoft partner to use generative AI for better EHRs. Healthcare IT News, 2023. Accessed: February 5, 2024.
  61. An extensive benchmark study on biomedical text generation and mining with ChatGPT. Bioinformatics, 39(9):btad557, 2023.
  62. Thomas Lancaster. Artificial intelligence, text generation tools and ChatGPT–Does digital watermarking offer a solution? International Journal for Educational Integrity, 19(1):10, 2023.
  63. Identifying women with postdelivery posttraumatic stress disorder using natural language processing of personal childbirth narratives. American Journal of Obstetrics and Gynecology MFM, 5(3):100834, 2023.
  64. Bishal Lamichhane. Evaluation of ChatGPT for NLP-based mental health applications. arXiv preprint arXiv:2303.15727, 2023.
  65. The AI Revolution in Medicine: GPT-4 and Beyond. Pearson, 2023.
  66. Using ChatGPT in medical research: Current status and future directions. Journal of Multidisciplinary Healthcare, pages 1513–1520, 2023.
  67. The capability of ChatGPT in predicting and explaining common drug-drug interactions. Cureus, 15(3), 2023.
  68. Developing a deep learning natural language processing algorithm for automated reporting of adverse drug reactions. Journal of Biomedical Informatics, 137:104265, 2023.
  69. Review of natural language processing in pharmacology. Pharmacological Reviews, 75(4):714–738, 2023.
  70. Cost of prescription drug–related morbidity and mortality. Annals of Pharmacotherapy, 52(9):829–837, 2018.
  71. Worldwide withdrawal of medicinal products because of adverse drug reactions: A systematic review and analysis. Critical Reviews in Toxicology, 46(6):477–489, 2016.
  72. How much do clinical trials cost? Nature Reviews Drug Discovery, 16(6):381–382, 2017.
  73. Multi-purposely dynamic use of social media for health purposes: Scooping review of systematic reviews. International Journal of Advanced Research in Biological Sciences, 9(6):92–108, 2022.
  74. Social media use for health purposes: Systematic review. Journal of Medical Internet Research, 23(5):e17917, 2021.
  75. Bryce Boe. PRAW: The Python Reddit API Wrapper. 2023. Accessed January 25, 2024.
  76. Eric Sayers. E-Utilities Quick Start. 2023. Accessed January 25, 2024.
  77. Biopython: Python tools for computational biology. ACM Sigbio Newsletter, 20(2):15–19, 2000.
  78. ScispaCy: Fast and robust models for biomedical natural language processing. arXiv preprint arXiv:1902.07669, 2019.
  79. Anjali Ganesh Jivani et al. A comparative study of stemming algorithms. International Journal of Computer Applications in Technology, 2(6):1930–1938, 2011.
  80. Nicolas Woloszko. Tracking activity in real time with Google Trends. OECD iLibrary, 2020.
  81. Predicting the frequencies of drug side effects. Nature Communications, 11(1):4575, 2020.
  82. Modeling polypharmacy side effects with graph convolutional networks. Bioinformatics, 34(13):i457–i466, 2018.
  83. The igraph software package for complex network research. InterJournal, Complex Systems, 1695(5):1–9, 2006.
  84. Dynamic clustering in social networks using louvain and infomap method. In 2016 Third European Network Intelligence Conference (ENIC), pages 61–68. IEEE, 2016.
  85. Worldwide Epidemic of Obesity. In Obesity and obstetrics, pages 3–8. Elsevier, 2020.
Citations (3)
View on Semantic Scholar

Summary

No one has generated a summary of this paper yet.

Sign Up to Summarize

Paper to Video (Beta)

No one has generated a video about this paper yet.

Sign Up to Generate All Videos Subscribe on YouTube

Whiteboard

No one has generated a whiteboard explanation for this paper yet.

Sign Up to Generate

Open Problems

We haven't generated a list of open problems mentioned in this paper yet.

Generate Now

Continue Learning

We haven't generated follow-up questions for this paper yet.

Generate Now

Collections

Sign up for free to add this paper to one or more collections.

Sign Up